Last reviewed · How we verify
Pooled human plasma
Pooled human plasma is used as a treatment for various conditions by providing a source of essential proteins and clotting factors.
Pooled human plasma is used as a treatment for various conditions by providing a source of essential proteins and clotting factors. Used for Hemophilia A, Hemophilia B, Congenital clotting factor deficiencies.
At a glance
| Generic name | Pooled human plasma |
|---|---|
| Sponsor | Turku University Hospital |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Pooled human plasma is a mixture of blood plasma from multiple donors, which is then used to treat patients with deficiencies in clotting factors or other proteins. This treatment can help to restore normal blood clotting and prevent bleeding complications.
Approved indications
- Hemophilia A
- Hemophilia B
- Congenital clotting factor deficiencies
Common side effects
- Infection
- Allergic reactions
- Pain at injection site
Key clinical trials
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (PHASE3)
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (PHASE3)
- Management of Children With Persistent ITP, A Novel Approach (NA)
- Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis (PHASE3)
- A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). (PHASE2)
- Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease (PHASE2)
- PEP on a Skin Graft Donor Site Wound (PHASE1)
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pooled human plasma CI brief — competitive landscape report
- Pooled human plasma updates RSS · CI watch RSS
- Turku University Hospital portfolio CI